Abstract
Objectives: Based on an analysis of the potential consequences of disclosing AD suspicions from respective research and using the research ethical principle of non-maleficence, the authors of this paper argue for the thesis that the benefits of early AD detection in research outweigh the risk of potential adverse effects only in cases where studies are conducted with symptomatic people actively seeking for support, e.g. as they utilize the services of memory clinics.
Conclusion: In the case of non-symptomatic volunteers, the result of the risk-benefit-assessment seems to be less distinctive. Given that disclosing results can, at least initially, cause severe distress and harm and taking into account that research examinations have a significantly increased risk of producing false-positive findings, we suggest to make use of a research-ethical “princple of caution” that supports a restrictive disclosure policy for the second group of potential study participants. This differentiated view on the benefits of disclosed findings in AD research is reflected in recommendations for the set-up of return of result processes.
Keywords: Alzheimer's disease, early diagnosis, mild cognitive impairment, disclosure dilemmas, research ethics, risk benefit assessment.
Current Alzheimer Research
Title:The Ambivalence of Early Diagnosis – Returning Results in Current Alzheimer Research
Volume: 15 Issue: 1
Author(s): Pia Erdmann*Martin Langanke
Affiliation:
- Faculty of Theology, Systematic Theology, University of Greifswald, Greifswald,Germany
Keywords: Alzheimer's disease, early diagnosis, mild cognitive impairment, disclosure dilemmas, research ethics, risk benefit assessment.
Abstract: Objectives: Based on an analysis of the potential consequences of disclosing AD suspicions from respective research and using the research ethical principle of non-maleficence, the authors of this paper argue for the thesis that the benefits of early AD detection in research outweigh the risk of potential adverse effects only in cases where studies are conducted with symptomatic people actively seeking for support, e.g. as they utilize the services of memory clinics.
Conclusion: In the case of non-symptomatic volunteers, the result of the risk-benefit-assessment seems to be less distinctive. Given that disclosing results can, at least initially, cause severe distress and harm and taking into account that research examinations have a significantly increased risk of producing false-positive findings, we suggest to make use of a research-ethical “princple of caution” that supports a restrictive disclosure policy for the second group of potential study participants. This differentiated view on the benefits of disclosed findings in AD research is reflected in recommendations for the set-up of return of result processes.
Export Options
About this article
Cite this article as:
Erdmann Pia *, Langanke Martin , The Ambivalence of Early Diagnosis – Returning Results in Current Alzheimer Research, Current Alzheimer Research 2018; 15 (1) . https://dx.doi.org/10.2174/1567205014666170908101237
DOI https://dx.doi.org/10.2174/1567205014666170908101237 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews Visual Spatial Attention Training Improve Spatial Attention and Motor Control for Unilateral Neglect Patients
CNS & Neurological Disorders - Drug Targets Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease
Current Aging Science Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists
Current Pharmaceutical Design Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Alzhemed: A Potential Treatment for Alzheimers Disease
Current Alzheimer Research Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry The Impact of Angiotensin-Converting Enzyme Gene on Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease
Current Alzheimer Research Patents in Targets and Drugs for Insulin Resistance: Correlation with Inflammatory Mediators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses
Current Alzheimer Research Editorial (Thematic Issue: Medicinal Chemistry: Neurological and Endocrinological Disorders)
Medicinal Chemistry Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research Amyotrophic Lateral Sclerosis: A Genetic Point of View
Current Molecular Medicine The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews The Association of MME microRNA Binding Site Polymorphism with the Risk of Late Onset Alzheimer’s Disease in Northern Han Chinese
Current Neurovascular Research β-Amyloid, Neuronal Death and Alzheimers Disease
Current Molecular Medicine